Skip To Main Content
Omor Ibne Ehsan on Muck Rack

Omor Ibne Ehsan

Dhaka
As seen in: Insider Monkey, MSN, MSN Ireland, Yahoo Life, Markets Insider, Aol, Yahoo Finance, Yahoo Finance Canada, Yahoo Finance Singapore, Flipboard, Yahoo Noticias and
Freelance Financial Writer on InvestorPlace
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Omor Ibne

Contact Omor Ibne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Boston Gin Company -

|
By Omor Ibne Ehsan
| bostonginco.com
The last time you heard of Moderna (MRNA) was likely because of its mRNA Covid vaccine, but that same tech, once administered en masse, could soon become a life-changing, specialized cure for cancers. The recent breakthrough came from its intismeran autogene, or more formally mRNA-4157/V940, Moderna's personalized mRNA cancer therapy developed alongside Merck (MRK), which met its primary recurrence-free survival endpoint in a late-stage melanoma trial.
Open in Who Shared View Duplicates (89) Issue with article?

Tesla vs. SpaceX: Which Musk Stock Offers the Better Bet on the Future?

|
By Omor Ibne Ehsan
| 24/7 Wall Street Verified
By Omor Ibne Ehsan Published Aug 21, 3:00PM EDT Tesla (TSLA) margin collapsed to 1% on record deliveries, while SpaceX (SPCX) grew revenue 92% with adjusted EBITDA surging 191%. Starlink's 12 million subscribers and zero enterprise customer losses give SpaceX recurring cash flow Tesla's autonomy business still can't match.
Open in Who Shared Issue with article?

Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

|
By Omor Ibne Ehsan
| Barchart
The last time you heard of Moderna (MRNA) was likely because of its mRNA Covid vaccine, but that same tech, once administered en masse, could soon become a life-changing, specialized cure for cancers. The recent breakthrough came from its intismeran autogene, or more formally mRNA-4157/V940, Moderna's personalized mRNA cancer therapy developed alongside Merck (MRK), which met its primary recurrence-free survival endpoint in a late-stage melanoma trial.
Open in Who Shared Issue with article?
See all 8,751 articles